Molecular Infectious Diseases

Molecular screening test for detection of the human papilloma virus (HPV) and for the prevention of cervical cancer. HPV Screening + genotyping (High + Low Risk): Identification of 28 HPV genotypes: 19 high risk HPV genotypes (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59 , 66, 68, 69, 73, 82) and 9 low-risk HPV genotypes (6, 11, 40, 42, 43, 44, 54, 61, 70). HPV Screening + genotyping (High Risk): Identification of 14 high risk HPV genotypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.

Molecular test aimed at detecting the messenger RNA (mRNA) of the HPV genotypes at the highest oncogenic risk, identifying its biological activity, with high potential for persistence and degeneration of the cervical lesion.

An innovative molecular test for the management of cervical cancer, aimed at detecting the circulating free DNA of the Human Papilloma virus (HPV cfDNA) in the blood of patients with cervical cancer or patients with HPV-related tumors.

GENOMICA is pleased to present the algorithm for the use of molecular tests in the management of HPV infections and related oncological risks. In this short video we explain how to integrate our molecular tests into clinical practice and where they fit into the various phases of the patient journey of patients with suspected or confirmed HPV infection.

A line of advanced tests aimed at providing information on the health status of the vaginal canal in relation to possible dysbiosis, underlying infections and reproductive failures related to the composition of the vaginal microbiota. The purpose of the test is to restore the health of the vaginal canal, identifying the presence of any unfavorable microenvironment.

An advanced test that investigates the endometrial microbiome, establishing the optimal uterine microbial environment for embryonic implantation, thus improving the chances of pregnancy in couples with history of reproductive failures